List of Antibody Drug Conjugates Companies in Germany - 8

What we do: we supply therapeutic molecules of clinical-grade quality for R&D and early drug development. Our solution: we repackage pharmaceuticals. So, we offer aliquots of clinical-grade mAbs, bs-mAbs, fusion proteins, ADCs, and other biologics as laboratory consumables. As an additional service, we provide analytical data to accompany each aliquot. Your advantage: you can order therapeutic molecules in clinical-grade quality as research consumables. Fast . Easy. Cost efficient.

Heidelberg Pharma AG based in Ladenburg, Germany, is a biopharmaceutical company listed on the Frankfurt Stock Exchange in the Regulated Market / Prime Standard. Heidelberg Pharma is focused on oncology and is the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary platform is being applied to develop the Company’s own therapeutic ATACs and third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA-ATAC for multiple myeloma. Former clinical assets MESUPRON® and REDECTANE® have been partnered. Our mission is to research and develop therapies for cancer patients enabling them to receive a targeted and tailor-made course of treatment that is both highly effective and as well-tolerated as possible.

Transforming proteins into pioneering drugs ProJect Pharmaceutics, based in Martinsried/Munich, Germany, transforms proteins, peptides and delicate small molecules into pioneering drugs. ProJect Pharmaceutics adds value to client´s bio-pharmaceutical products by applying an innovative concept of development called Advaceutics. Based on the Advaceutics concept, ProJect Pharmaceutics designs optimized formulations and delivery systems for biologics that are stable, convenient and safe. Tailored to these optimized systems the company develops cost-effective manufacturing processes and transfers those from its own pilot labs to large-scale manufacturing. ProJect Pharmaceutics makes sure that investigational products, biosimilars as well as "bio-betters" are developed effectively and will run smoothly in clinical and commercial scale GMP manufacturing. We offer: • predictive formulation analytics • formulation development including in-depth protein analytics • lyophilization process development and optimization • lyophilization in dual chamber prefilled syringe • development of liposomal formulations, producible by simple stirring • manufacturing of preclinical study material • technology-transfer including scale-up to GMP-manufacturer We deliver: • optimized formulations for biopharmaceuticals • tailored manufacturing processes and transfer to GMP manufacturing • development reports ready for submission to the authorities for registration

SYNIMMUNE GmbH is a biotechnology company focusing on the development of novel mono- and bispecific antibodies for improved immunotherapy of cancer.

Tacalyx develops the next generation of anti-Cancer therapeutics in indications with high medical need

Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.

VERAXA Biotech specializes in ADC development combining cutting-edge solutions for targeted antibody discovery and bioconjugation. Through biochemical and technological innovation, we strive to transform the way antibodies and antibody-drug conjugates (ADCs) are created to develop more effective and safe therapies for patients. With our transformative technologies, we can streamline and derisk early bioconjugate development. We have established a rich pipeline of proprietary ADCs and are collaborating with a number of partners to provide access to our unique research & development capabilities going from target to antibody to ADC.

YUMAB Company profile The German biotech company YUMAB was founded in 2012 as spin-off the University of Braunschweig. In little more than five years, YUMAB (a phonetic play on “HUMAB”, which stands for “human monoclonal antibody and in which the “Y” symbolizes the well-known antibody structure) has become a global player in human monoclonal antibody (mAb) development, and drives the general trend in the immunotherapy space toward the use of fully human mAbs for therapeutic applications. The YUMAB® antibody platform provides rapid, reliable and robust development of “state-of-the-art” and “next-generation” fully human antibodies. The technologies base on more than 28 years of continuous research and development of our founders, who are well recognized scientific experts in the field of recombinant antibody technologies and who have an outstanding track-record in academic and industrial research. YUMAB provides optimized antibody development solutions for: i) discovery & development of novel, fully human antibodies, ii) antibody engineering & humanization, and iii) personalized & custom libraries Key features of the YUMAB® platform are: i) world’s best, naturally derived, universal, human antibody libraries (>10e11) ii) powerful in vitro selection technologies including on-cells-selection for difficult targets iii) large scale screening platforms iv) comprehensive portfolio of antibody engineering & humanization technologies v) compatibility to all therapeutic antibody formats YUMAB provides fee for service solutions with attractive pricing and flexible license models & options as well as collaborative projects. YUMAB’s research & development unit performs internal pipeline and partnered projects ranging from the development of novel antibody therapeutics to the discovery to novel targets technologies. Our mission is to make the best human antibody technologies available for the early development to accelerate translation of research from bench to bedsite.